Economic Superiority Claims, Manufacturer/Payer Relationships Ripe For Enforcement Scrutiny
Executive Summary
The era of big pharma off-label promotion cases may be coming to a close, but federal prosecutors are eyeing other industry practices for enforcement, including unsupported promotional claims of economic superiority and superior efficacy, and manipulation of the average sales price system.